Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
185 participants
OBSERVATIONAL
2010-04-27
2021-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
NCT05237245
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT01741792
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521
A Registry for People With T-cell Lymphoma
NCT05978141
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02596971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Previously treated with T-VEC
Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
Information collection
Q3M Information collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Information collection
Q3M Information collection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment and participation, including long-term follow-up (if applicable) in that trial.
Exclusion Criteria
Subject currently participating, including for long-term follow-up (if applicable), in other Amgen-sponsored talimogene laherparepvec clinical trial.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
St Joseph Heritage Healthcare
Santa Rosa, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Florida Hospital Memorial Division
Daytona Beach, Florida, United States
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Oncology Specialists SC
Park Ridge, Illinois, United States
Investigative Clinical Research of Indiana, LLC
Indianapolis, Indiana, United States
Allina Health System dba Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
Saint Louis University Hospital
St Louis, Missouri, United States
Morristown Medical Center
Morristown, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States
Wake Forest Baptist Health Medical Center
Winston-Salem, North Carolina, United States
Gabrail Cancer Center, LLC
Canton, Ohio, United States
Providence Oncology and Hematology Care Eastside
Portland, Oregon, United States
Greenville Health System Institute for Translational Oncology Research
Greenville, South Carolina, United States
The West Clinic PC dba West Cancer Center
Germantown, Tennessee, United States
Henry Joyce Cancer Center
Nashville, Tennessee, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Intermountain Medical Center
Murray, Utah, United States
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States
Wheaton Franciscan Healthcare
Franklin, Wisconsin, United States
Landeskrankenhaus Salzburg
Salzburg, , Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, , Austria
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Hopital Ambroise Pare
Boulogne-Billancourt, , France
Centre Hospitalier Universitaire de Nantes, Hôpital Hôtel Dieu
Nantes, , France
University Hospital
Heidelberg, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
General Hospital of Athens Laiko
Athens, , Greece
Metropolitan Hospital
Athens, , Greece
Bioclinic of Thessaloniki
Thessaloniki, , Greece
Pecsi Tudomanyegyetem Klinikai Kozpont
Pécs, , Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar
Szeged, , Hungary
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Bergamo, , Italy
IRCCS Istituto Europeo di Oncologia
Milan, , Italy
Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
Siena, , Italy
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
Warsaw, , Poland
FSBI N N Blokhin Russian Oncology Research Center Ministry of Health of Russian Federation
Moscow, , Russia
FSBI Scientific and Research Oncology Institute named after N N Petrov
Saint Petersburg, , Russia
Wilgers Oncology Centre
Pretoria, , South Africa
Yonsei University Health System Severance Hospital
Seoul, , South Korea
Onkologikoa
Donostia / San Sebastian, Basque Country, Spain
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, Spain
Hospital General Universitario de Valencia
Valencia, Valencia, Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Kantonsspital Graubuenden
Chur, , Switzerland
Hopitaux Universitaires de Geneve
Geneva, , Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, , Switzerland
Universitaetsspital Zuerich
Zuerich Flughafen, , Switzerland
Guys and St Thomas Hospital
London, , United Kingdom
Royal Marsden Hospital
London, , United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Metropolitan Borough of Wirral, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20120139
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.